185 related articles for article (PubMed ID: 35195923)
41. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
42. Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea.
Yoon JH; Jeon MJ; Kim M; Hong AR; Kim HK; Shin DY; Kim BH; Kim WB; Shong YK; Kang HC
PLoS One; 2020; 15(8):e0238207. PubMed ID: 32841270
[TBL] [Abstract][Full Text] [Related]
43. [Clinical characteristics and prognostic analysis of double primary breast cancer and thyroid cancer].
Zhai J; Kong XY; Fang Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1287-1291. PubMed ID: 34915638
[No Abstract] [Full Text] [Related]
44. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
Piek MW; de Boer JP; van Duijnhoven F; van der Wal JE; Vriens M; van Leeuwaarde RS; van der Ploeg IMC
BMC Cancer; 2022 Sep; 22(1):1018. PubMed ID: 36163009
[TBL] [Abstract][Full Text] [Related]
45. Localization techniques for guided surgical excision of non-palpable breast lesions.
Chan BK; Wiseberg-Firtell JA; Jois RH; Jensen K; Audisio RA
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009206. PubMed ID: 26718728
[TBL] [Abstract][Full Text] [Related]
46. Accrual issues for chemoprevention trials: the example of the 4-HPR study for the prevention of contralateral breast cancer.
Camerini T; De Palo G; Mariani L; Marubini E; Costa A; Veronesi U
Tumori; 1999; 85(4):299-303. PubMed ID: 10587038
[TBL] [Abstract][Full Text] [Related]
47. [Hormonal therapy in oncologic treatment: pathogenic hypotheses and interactions between thyroid and breast pathologies].
Parmeggiani D; Malinconico FA; Moccia G; Idà DN; Ripa C; Scala R; Foroni F; Gilio F; Cognetti C; Iside G; Agresti M
Tumori; 2003; 89(4 Suppl):215-9. PubMed ID: 12903598
[TBL] [Abstract][Full Text] [Related]
48. Treatments for breast engorgement during lactation.
Zakarija-Grkovic I; Stewart F
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD006946. PubMed ID: 32944940
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Medical Surveillance and Incidence of Post-September 11, 2001, Thyroid Cancer in World Trade Center-Exposed Firefighters and Emergency Medical Service Workers.
Colbeth HL; Genere N; Hall CB; Jaber N; Brito JP; El Kawkgi OM; Goldfarb DG; Webber MP; Schwartz TM; Prezant DJ; Zeig-Owens R
JAMA Intern Med; 2020 Jun; 180(6):888-895. PubMed ID: 32310290
[TBL] [Abstract][Full Text] [Related]
50. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
Lin CY; Lin CL; Huang WS; Kao CH
J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
[TBL] [Abstract][Full Text] [Related]
51. Multiple primary thyroid and breast cancer in Israel, 1960-1976.
Stein M; Bartal A; Kuten A; Loberant N; Hershkovitz R; Masalcha H; Robinson E
S Afr Med J; 1989 Dec; 76(12):664-6. PubMed ID: 2595504
[TBL] [Abstract][Full Text] [Related]
52. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
53. Breast surgery for metastatic breast cancer.
Tosello G; Torloni MR; Mota BS; Neeman T; Riera R
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011276. PubMed ID: 29542106
[TBL] [Abstract][Full Text] [Related]
54. [Analysis of clinicopathological features of patients with simple breast cancer and breast cancer with thyroid cancer].
Yang HB; Gao JN; Song WZ
Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):624-627. PubMed ID: 31434455
[No Abstract] [Full Text] [Related]
55. Prospective study of transfusion history and thyroid cancer incidence among females in Japan.
Fujino Y; Tamakoshi A; Hoshiyama Y; Mikami H; Okamoto N; Ohno Y; Yoshimura T
Int J Cancer; 2004 Nov; 112(4):722-5. PubMed ID: 15382057
[TBL] [Abstract][Full Text] [Related]
56. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.
Shim SR; Kitahara CM; Cha ES; Kim SJ; Bang YJ; Lee WJ
JAMA Netw Open; 2021 Sep; 4(9):e2125072. PubMed ID: 34533571
[TBL] [Abstract][Full Text] [Related]
57. Incidence of thyroid cancer in women in relation to known or suspected risk factors for breast cancer.
McTiernan A; Weiss NS; Daling JR
Cancer Res; 1987 Jan; 47(1):292-5. PubMed ID: 3791213
[TBL] [Abstract][Full Text] [Related]
58. Familial risks for nonmedullary thyroid cancer.
Hemminki K; Eng C; Chen B
J Clin Endocrinol Metab; 2005 Oct; 90(10):5747-53. PubMed ID: 16030170
[TBL] [Abstract][Full Text] [Related]
59. The effect of thyroid dysfunction on breast cancer risk: an updated meta-analysis.
Tran TV; Kitahara CM; Leenhardt L; de Vathaire F; Boutron-Ruault MC; Journy N
Endocr Relat Cancer; 2023 Jan; 30(1):. PubMed ID: 36256851
[TBL] [Abstract][Full Text] [Related]
60. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
